Luminespib

Drug Profile

Luminespib

Alternative Names: AUY-922; NVP-AUY-922; VER-52296

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; Sarah Cannon Research Institute; SCRI Development Innovations; University of Texas M. D. Anderson Cancer Center; University of Toronto; Vernalis
  • Class Amides; Antineoplastics; Isoxazoles; Morpholines; Resorcinols; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Lymphoma; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Solid tumours
  • Discontinued Pancreatic cancer

Most Recent Events

  • 22 Jan 2017 M.D. Anderson Cancer Center and Novartis terminates a phase II trial due to limited response for Lymphoma (Second-line therapy or greater) in USA (NCT01485536)
  • 01 Jan 2017 Novartis terminates a phase II trial in Non-small-cell lung cancer (Metastatic disease, Late-stage disease, Recurrent, Second-line therapy or greater) due to futility data in USA, United Kingdom, Australia, France, Hong Kong, Israel, Italy, Japan, Netherlands, Norway, Poland, Singapore, South Korea, Spain, and Taiwan (NCT01646125)
  • 01 Jan 2016 Novartis completes a phase Ib trial in ALK-rearranged Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Australia, Italy, Singapore and Spain (NCT01772797)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top